167 related articles for article (PubMed ID: 37184818)
1. Effect of preparation method for radioactive iodine therapy on serum electrolytes.
Takata N; Miyagawa M; Okada T; Kawaguchi N; Fujimoto Y; Kouchi Y; Tsuruoka S; Uwatsu K; Kido T
Jpn J Radiol; 2023 Nov; 41(11):1247-1254. PubMed ID: 37184818
[TBL] [Abstract][Full Text] [Related]
2. The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy.
Lee SJ; Lee HY; Lee WW; Kim SE
Nucl Med Commun; 2014 Jul; 35(7):727-32. PubMed ID: 24709982
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin.
Cho YY; Kim SK; Jung JH; Hahm JR; Kim TH; Chung JH; Kim SW
Endocrine; 2019 May; 64(2):293-298. PubMed ID: 30471053
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
[TBL] [Abstract][Full Text] [Related]
5. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies.
Coerts HI; de Keizer B; Marlowe RJ; Verburg FA
Eur J Endocrinol; 2023 Feb; 188(2):. PubMed ID: 36655579
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
7. Preparation for radioactive iodine therapy is not a risk factor for the development of hyponatremia in thyroid cancer patients.
Kim J; Cho SG; Kang SR; Kwon SY; Cho DH; Cho JS; Song HC
Medicine (Baltimore); 2017 Feb; 96(5):e6004. PubMed ID: 28151897
[TBL] [Abstract][Full Text] [Related]
8. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Endocr Pract; 2013; 19(1):139-48. PubMed ID: 23186979
[TBL] [Abstract][Full Text] [Related]
9. Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer.
Coura-Filho GB; Willegaignon J; Buchpiguel CA; Sapienza MT
Thyroid; 2015 Dec; 25(12):1291-6. PubMed ID: 26446582
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults.
Schumm MA; Pyo HQ; Kim J; Tseng CH; Yeh MW; Leung AM; Chiu HK
Clin Endocrinol (Oxf); 2021 Aug; 95(2):344-353. PubMed ID: 33704813
[TBL] [Abstract][Full Text] [Related]
11. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Inoue M; Nakamura K; Mizowaki T
Ann Nucl Med; 2020 Oct; 34(10):736-741. PubMed ID: 32643022
[TBL] [Abstract][Full Text] [Related]
12. Hyperkalemia develops in some thyroidectomized patients undergoing thyroid hormone withdrawal in preparation for radioactive iodine ablation for thyroid carcinoma.
Horie I; Ando T; Imaizumi M; Usa T; Kawakami A
Endocr Pract; 2015 May; 21(5):488-94. PubMed ID: 25667379
[TBL] [Abstract][Full Text] [Related]
13. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
14. Influence of Levothyroxine With Recombinant Human Thyroid-Stimulating Hormone on Urinary Iodine Excretion Before Radioactive Iodine Administration.
Fujimoto K; Hataya Y; Okubo M; Matsuoka N
Endocr Pract; 2021 Oct; 27(10):1022-1027. PubMed ID: 33831554
[TBL] [Abstract][Full Text] [Related]
15. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.
Tala H; Robbins R; Fagin JA; Larson SM; Tuttle RM
J Clin Endocrinol Metab; 2011 Jul; 96(7):2105-11. PubMed ID: 21565788
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
17. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
[TBL] [Abstract][Full Text] [Related]
18. Absorbed dose coefficients for adult thyroid cancer patients undergoing radioiodine therapy.
Kwon TE; Pasqual E; Kitahara CM; Lee C
J Radiol Prot; 2023 May; 43(2):. PubMed ID: 37196645
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the incidence and influencing factors of hyponatremia before
Cao JJ; Yun CH; Xiao J; Liu Y; Wei W; Zhang W
World J Clin Cases; 2021 Dec; 9(36):11173-11182. PubMed ID: 35071548
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
